Silo Pharma Reports $1.2 Million Net Loss in Q2 2025, Revenue Stable at $18,025

Silo Pharma, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $1.2 million, or $0.19 per share, compared to a net loss of $931,779, or $0.31 per share, for the same period in 2024. For the first half of 2025, the company recorded a net loss of $2.2 million, up from $1.7 million in the prior year. Revenue remained stable at $18,025 for both the second quarter of 2025 and 2024, with total revenue for the first half of the year also unchanged at $36,051. The company’s gross profit for the quarter was $16,566, consistent with the previous year.

Operating expenses increased significantly, totaling $1.3 million for the second quarter of 2025, compared to $1.0 million in the same quarter of 2024. This rise was primarily driven by a substantial increase in research and development costs, which surged to $717,247 from $392,824 year-over-year, reflecting the company's commitment to advancing its product candidates. Compensation expenses also rose, attributed to higher stock-based compensation and payroll costs. In contrast, professional fees decreased, indicating a reduction in investor relations and consulting expenses.

Silo Pharma's balance sheet as of June 30, 2025, showed total assets of $6.7 million, down from $7.4 million at the end of 2024. Current assets decreased to $6.4 million, primarily due to a reduction in short-term investments, which fell to $1.9 million from $3.2 million. However, cash and cash equivalents increased to $4.3 million, up from $3.9 million, providing the company with a working capital of $5.3 million. Current liabilities also decreased significantly, contributing to a more favorable liquidity position.

Strategically, Silo Pharma has been active in expanding its product pipeline and enhancing its operational capabilities. The company is focused on developing novel therapeutics for conditions such as PTSD and fibromyalgia, with ongoing research agreements with institutions like Columbia University. Recently, Silo Pharma entered into a new agreement with the University of Maryland, Baltimore, which allows for the evaluation of certain intellectual property related to central nervous system-homing peptides. Additionally, the company has initiated a cryptocurrency treasury strategy aimed at acquiring leading digital assets, reflecting a diversification of its business model.

Looking ahead, Silo Pharma anticipates continued investment in research and development to advance its product candidates, particularly SPC-15 and SP-26, while managing its operational costs. The company believes it has sufficient cash reserves to meet its obligations for at least the next twelve months, despite the ongoing net losses. The management remains optimistic about the potential of its therapeutic developments and the strategic direction of its cryptocurrency initiatives.